tbuckley/cabot-search huggingface dataset:
Assessment of minimal phototoxic dose following 8-methoxypsoralen bath: maximal reaction on average after 5 days
Authors: S. Behrens-Williams, C. Gruss, M. Grundmann-Kollmann, R.U. Peter, M. Kerscher
Journal: British Journal of Dermatology (2000)

An essential procedure before starting bath psoralen ultraviolet (UV) A (PUVA) photochemotherapy is the evaluation of the minimal phototoxic dose (MPD), which is traditionally assessed 3 days after irradiation. However, there are no controlled studies supporting the 72 h peak of bath-PUVA erythema. The aim of this study was therefore to determine the exact time course of the erythematous reaction in human skin following bath-PUVA. For this purpose, the skin of 10 volunteers was exposed to 0.5-3.0 J/cm2 UVA directly after a 20-min 8-methoxypsoralen bath (0.5 mg/L, 37 degrees C). At 24, 48, 72, 96, 120 and 144 h (1-6 days) after irradiation, the MPD and the erythema sum score (ESS) were determined in each subject. The results showed a maximal erythematous reaction on average 5 days after irradiation. The mean MPD gradually decreased from day 2 (> 3.0 J/cm2) to day 5 (mean +/- SD 1.15 +/- 0.63 J/cm2) and started to increase at day 6 (mean +/- SD 1.6 +/- 0.52 J/cm2). The mean +/- SD ESS correspondingly increased from day 2 (0 +/- 0) to day 5 (10.5 +/- 3. 7) with a decrease at day 6 (7.5 +/- 3.1) (difference between day 3 and beyond statistically significant at P < 0.05). As our study indicates a maximal erythematous reaction to the bath-PUVA up to 5 days after irradiation, the traditional MPD assessment at 3 days generates a risk of phototoxic side-effects within the phototherapy course by underestimating the phototoxic effect in some patients. These findings contribute towards a more defined understanding of the kinetics of the phototoxic reaction in bath-PUVA therapy.
Graded reduction of Pafah1b1 (Lis1) activity results in neuronal migration defects and early embryonic lethality
Authors: Shinji Hirotsune, Mark W. Fleck, Michael J. Gambello, Gregory J. Bix, Amy Chen, Gary D. Clark, David H. Ledbetter, Chris J. McBain, Anthony Wynshaw-Boris
Journal: Nature Genetics (1998)
Calcipotriol ointment and cream or their vehicles applied immediately before irradiation inhibit ultraviolet B-induced erythema
Authors: M.A. De Rie, S. Di Nuzzo, S. Brands, A.B. Hansen, J.D. Bos
Journal: British Journal of Dermatology (2000)

Abstract Results of ultraviolet (UV) B phototherapy can be improved by the application of calcipotriol, but studies are needed to decide how the two treatments should be combined. We studied the effect of UVB after application of calcipotriol ointment (50 μg g−1) and calcipotriol cream (50 μg g−1) and determined the optimal time of application of calcipotriol when combined with UVB phototherapy (280–350 nm), in a single-blinded randomized vehicle-controlled study of 37 healthy adult volunteers. Calcipotriol ointment or cream was applied randomly on five areas on the back at different time intervals from UVB irradiation. One area was left untreated as the control. Application times were the evening before, the morning before, 2 h before, immediately before, and immediately after irradiation. UVB irradiation was administered by TL20W/12 fluorescent tube lamps at increasing doses (20, 25, 32, 40, 50 and 64 mJ cm−2) to six subunits of each test area. Clinical assessment was performed 24 h after UVB irradiation by a blinded investigator. Calcipotriol ointment and cream were applied in 19 and 18 subjects, respectively, and erythema was measured for each application time quantified. We found that erythemal reactions were significantly smaller when calcipotriol ointment or cream was applied immediately before irradiation compared with all other application times. To explain these findings, a vehicle control study was performed. No difference in erythema was seen between calcipotriol medication and the vehicle controls. Spectrophotometric analysis of the calcipotriol cream and ointment showed no UV absorbance in the UVB range. No signs of photosensitization were noted. In conclusion, the vehicles of the calcipotriol ointment and cream inhibit the induction of erythema by UVB irradiation if applied immediately before phototherapy. Consequently, calcipotriol ointment and cream should not be applied directly before UVB irradiation; however, they may be applied at any time up to 2 h prior to or immediately after UVB irradiation. Possible explanations for this sunscreen activity are discussed.
Nutrient Sensor in the Brain Directs the Action of the Brain-Gut Axis in Drosophila
Authors: Monica Dus, Jason Sih-Yu Lai, Keith M. Gunapala, Soohong Min, Timothy D. Tayler, Anne C. Hergarden, Eliot Geraud, Christina M. Joseph, Greg S.B. Suh
Journal: Neuron (2015)
A review of the dynamics and severity of the pandemic A(H1N1) influenza virus on Réunion Island, 2009
Authors: E. D'Ortenzio, P. Renault, M.C. Jaffar-Bandjee, B.A. Gaüzère, M. Lagrange-Xélot, A. Fouillet, P. Poubeau, A. Winer, A. Bourde, F. Staikowsky, P. Morbidelli, E. Rachou, F. Thouillot, A. Michault, L. Filleul
Journal: Clinical Microbiology and Infection (2010)
Oral proteasome inhibitor (NPI-0052) enhances sensitivity to combination Gemcitabine and Erbitux in a pancreatic cancer xenograft model
Authors: James C. Cusack, Rong Liu, Lijun Xia, David Ljungman, Rena Bahjat, Michael A. Palladino
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

4943 

Pancreatic cancer is one of the most resistant cancers to chemotherapy and irradiation. A variety of resistance mechanisms have been demonstrated in pancreatic cancer including the activation of nuclear transcription factor kappa B (NF-κB) and the dysregulation of the epidermal growth factor receptor (EGFR). We have previously demonstrated in vitro that the proteasome inhibitor NPI-0052 suppresses both constitutive and chemotherapy-induced NF-κB activation, but does not stabilize p53 expression, suggesting that treatment induced responses are mediated through p53-independent pathways. The current study was performed to determine if oral administration of a potent proteasome inhibitor NPI-0052 (Nereus Pharmaceuticals, San Diego) could alter the sensitivity to the combination treatment of gemcitabine (Gemzar, Eli Lily, Indianapolis, IN) and the antibody to EGFR (Erbitux, Imclone, Princeton, NJ) in a pancreatic cancer xenograft model. To determine the effect of proteasome inhibition on treatment response, panc-1 tumors were established by injecting 5 x 106 cells in the flank of female nude mice (nu/nu, 4-5 wks, 18-20g). Treatments were initiated once the tumors reached a mean diameter of 10 mm. Treatment groups (7 mice/group) received twice-weekly combination treatment with Erbitux 33mg/kg i.p., Gemzar 80mg/kg, and/or NPI-0052 0.25mg/kg. We found that the addition of NPI-0052 to the different treatment regimens resulted in an enhanced tumor growth response, including a 2-fold greater response to gemcitabine alone (p<0.001,T test), a 1.8-fold greater response to treatment with gemcitabine/Erbitux (p<0.01), and a 1.3-fold enhanced response to treatment with NPI-0052 alone compared to gemcitabine alone (p<0.05). These results demonstrate that the addition of NPI-0052 significantly enhanced tumor growth response to all treatments studied. Additional studies are underway to evaluate the potential of using orally administered NPI-0052 as an adjunct to combination chemo-and molecular therapy in pancreatic cancer.



![Figure][1]  [1]: pending:yes
Time to Test Incentives to Increase Organ Donation
Authors: Sally Satel, David C. Cronin
Journal: JAMA Internal Medicine (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
The SWIRM domain: a conserved module found in chromosomal proteins points to novel chromatin-modifying activities
Authors: L Aravind, Lakshminarayan M Iyer
Journal: Genome biology (2002)

Eukaryotic chromosomal components, especially histones, are subject to a wide array of covalent modifications and catalytic reorganization. These modifications have an important role in the regulation of chromatin structure and are mediated by large multisubunit complexes that contain modular proteins with several conserved catalytic and noncatalytic adaptor domains. Using computational sequence-profile analysis methods, we identified a previously uncharacterized, predicted α-helical domain of about 85 residues in chromosomal proteins such as Swi3p, Rsc8p, Moira and several other uncharacterized proteins. This module, termed the SWIRM domain, is predicted to mediate specific protein-protein interactions in the assembly of chromatin-protein complexes. In one group of proteins, which are highly conserved throughout the crown-group eukaryotes, the SWIRM domain is linked to a catalytic domain related to the monoamine and polyamine oxidases. Another human protein has the SWIRM domain linked to a JAB domain that is involved in protein degradation through the ubiquitin pathway. Identification of the SWIRM domain could help in directed experimental analysis of specific interactions in chromosomal proteins. We predict that the proteins in which it is combined with an amino-oxidase domain define a novel class of chromatin-modifying enzymes, which are likely to oxidize either the amino group of basic residues in histones and other chromosomal proteins or the polyamines in chromatin, and thereby alter the charge distribution. Other forms, such as KIAA1915, may link chromatin modification to ubiquitin-dependent protein degradation.
A CASE OF HEMOCHROMATOSIS WITH ALMOST COMPLETE ABSENCE OF SKIN PIGMENT, AND WITH FATAL RUPTURE OF AN ESOPHAGEAL VARIX
Authors: Maynard E. Holmes
Journal: Annals of Internal Medicine (1939)

Case Reports1 December 1939A CASE OF HEMOCHROMATOSIS WITH ALMOST COMPLETE ABSENCE OF SKIN PIGMENT, AND WITH FATAL RUPTURE OF AN ESOPHAGEAL VARIXMAYNARD E. HOLMES, M.D., F.A.C.P.MAYNARD E. HOLMES, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-13-6-1075 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptHemochromatosis, also known as bronzed diabetes and pigment cirrhosis, is said to be a rare disease. Sheldon3in his recent book on hemochromatosis has made a most thorough and extensive review of the literature. In his painstaking search he was able to collect 311 cases which could be accepted as genuine instances of the disease. He cites Stewart as having collected records of but 52 cases of hemochromatosis from 38,095 autopsies performed in several British hospitals. In Bellevue hospital in New York City only four cases of this disease were noted in 5000 autopsies.1Butt and Wilder2have recently reported...References1. BLANTONHEALY WBW: Hemochromatosis, Arch. Int. Med., 1921, xxvii, 406-420. CrossrefGoogle Scholar2. BUTTWILDER HRWM: Hemochromatosis: A report of thirty cases diagnosed during life, Proc. Staff Meet. Mayo Clin., 1937, xii, 625-627. Google Scholar3. SHELDON JH: Hemochromatosis, Humphrey Milford, 1935, Oxford University Press, London. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Syracuse, New York*Received for publication June 29, 1938.The author is indebted to Dr. Shields Warren of Boston for having reviewed the microscopic sections from this case and for his helpful comment. In making the photomicrographs the background cellular structures were sacrificed somewhat to bring out the pigment more clearly. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byALDOSTERONE DEFICIENCY IN A PATIENT WITH IDIOPATHIC HAEMOCHROMATOSISPHLEBOTOMY FOR HÆMOCHROMATOSIS EFFECT OF REMOVING 52 PINTS OF BLOOD IN SIXTEEN MONTHS 1 December 1939Volume 13, Issue 6Page: 1075-1081KeywordsAutopsyHemochromatosis ePublished: 1 December 2008 Issue Published: 1 December 1939 PDF downloadLoading ...
Accelerated Approval Scrutinized
Authors: Mike Mitka
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Television Ads for e-Cigarettes Should Cease
Authors: Rita Rubin
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Netherton's syndrome: increased likelihood of diagnosis by examining eyebrow hairs
Authors: None Powell, None Dawber, None Ferguson, None Griffiths
Journal: British Journal of Dermatology (1999)

Netherton's syndrome is a rare autosomal recessive condition with variable expression. It comprises an ichthyosiform dermatitis and erythroderma of variable intensity and manifestations, associated with hair abnormalities. The pathognomonic finding (required for diagnosis) is that of trichorrhexis invaginata identified by light and scanning electron microscopic examination of hair shafts. This may be difficult to establish because the hair is sparse and not all hairs exhibit abnormalities. In one patient, cutaneous and hair problems had existed since infancy, and despite repeated examination of scalp hairs, the definitive diagnosis was made only by examining eyebrow hairs at the age of 30 years. We subsequently compared the number of diagnostic lesions found on scalp and eyebrow hairs from two other patients with previously diagnosed Netherton's syndrome. The density of lesions was greater in eyebrow than scalp hair, and furthermore, all eyebrow hairs had at least one lesion. It is proposed that microscopic examination, if possible, of both scalp and eyebrow hair from patients in whom Netherton's syndrome is suspected would increase the chance of a positive diagnosis.
Guidelines for Statistical Reporting in Articles for Medical Journals
Authors: JOHN C. BAILAR
Journal: Annals of Internal Medicine (1988)

The 1988 edition of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals includes guidelines for presenting statistical aspects of scientific research. The guidelines are intended to aid authors in reporting the statistical aspects of their work in ways that are clear and helpful to readers. We examine these guidelines for statistics using 15 numbered statements. Although the information presented relates to manuscript preparation, it will also help investigators in earlier stages make critical decisions about research approaches and protocols.
Mass spectrometry-based proteomic analysis of cutaneous cryoglobulinaemia in formalin-fixed tissues
Authors: W. Shon, A. Dogan, M.J. Camilleri, L.A. Erickson, T.J. Flotte
Journal: British Journal of Dermatology (2012)

Journal Article Mass spectrometry‐based proteomic analysis of cutaneous cryoglobulinaemia in formalin‐fixed tissues Get access W. Shon, W. Shon Departments of DermatologyLaboratory Medicine and Pathology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, U.S.A Search for other works by this author on: Oxford Academic Google Scholar A. Dogan, A. Dogan Laboratory Medicine and Pathology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, U.S.A Search for other works by this author on: Oxford Academic Google Scholar M.J. Camilleri, M.J. Camilleri Departments of Dermatology Search for other works by this author on: Oxford Academic Google Scholar L.A. Erickson, L.A. Erickson Departments of DermatologyLaboratory Medicine and Pathology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, U.S.A Search for other works by this author on: Oxford Academic Google Scholar T.J. Flotte T.J. Flotte Departments of DermatologyLaboratory Medicine and Pathology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, U.S.A Thomas J. Flotte. E‐mail: flotte.thomas@mayo.edu Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 168, Issue 5, 1 May 2013, Pages 1128–1130, https://doi.org/10.1111/bjd.12062 Published: 01 May 2013
Simultaneous determination of multiple end points in the screening of cytotoxic drugs, using laser-scanning fluorescence microplate cytometry.
Authors: James Wilson, Joanne Read, Patricia Hurley, Gerard Brady, Catherine Booth
Journal: Cancer Research (2007)

AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA

3230 

Aim: To determine whether fluorescence microplate cytometry can provide multiple data end points for assessment of cytotoxic drug action on adherent tumour cell lines in vitro .

Methods: The effects of three different cytotoxic agents (5-fluorouracil, cisplatin and irinotecan) on six cell lines (MCF-7, HT-29, A549, A375, PANC1 and LNCAP) were assessed. Cells were grown in 96 well plates. When in log-phase growth, cells were transferred to reduced serum medium and treated with cytotoxics. In live cells, at set times after treatment, multiple fluorescence-based methods were employed to measure cell viability, apoptosis and cell cycle parameters in both unfixed and fixed cells. Data acquisition and analysis were performed using an Acumen Explorer fluorescence microplate cytometer (TTP Labtech Ltd., Melbourn, Herts, UK.)

Results: Data on nuclear size, nuclear DNA content, BrdU labelling, caspase activity and plasma membrane activity could all be obtained for each adherent cell within a culture well. Dose-response relationships for each cytotoxic agent were determined using these data. Data outputs could be obtained in the form of graphs, true-colour well images and false-colour heat map images. Table 1 shows representative data for relative cell number, relative nuclear size and relative nuclear DNA content obtained from HT-29 cells, 48 hours after treatment with 5-FU.

Conclusion: Microplate cytometry can provide data on cell number, cell viability, apoptosis and cell cycle simultaneously in a high throughput format. This has been demonstrated in a range of cell lines exposed to different cytotoxic agents. The methods described greatly facilitate the rapid screening of novel agents against a range of standard standard cytotoxic agents.



![Table][1]  [1]: pending:yes
Mutations Help Predict Cancer Drug Response
Authors: Tracy Hampton
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal